Dahlbäck B
Department of Clinical Chemistry, University of Lund, University Hospital, Malmö, Sweden.
Haematologica. 1997 Jan-Feb;82(1):91-5.
Activated protein C (APC)-resistance, the most common risk factor for venous thrombosis described so far, is due to a single point mutation in the factor V gene. As a result, inactivation of factor-activated factor V by APC is impaired, which leads to a hypercoagulable state and a lifelong increased risk of thrombosis. The importance of protein S as an anticoagulant protein is illustrated by the association between protein S deficiency and venous thrombosis. The objective of this article is to examine the most recent advances on the role of factor V and protein S as cofactors to activated protein C.
The material examined in the present review includes several personal papers in this field, and articles and abstracts published in journals covered by the Science Citation Index.
Factors V and VIII are homologous, high molecular weight glycoproteins with similar functional properties. Factors Va and VIIIa bind to negatively charged phospholipid and function as high affinity receptors/cofactors for factors Xa and IXa, respectively. Factors Va and VIIIa account for at least a 10(3) increase in the rate of activation of prothrombin and factor Xa, respectively. The potent anticoagulant activity of APC is mediated by the degradation of factors VIIIa and Va, resulting in inhibition of both Xase and prothrombinase activities. APC specifically degrades the membrane-bound activated forms of factors V and VIII, whereas the unactivated factors V and VIII are poor substrates for APC. Mature human protein S is a single chain glycoprotein composed of multiple domains, including a thrombin-sensitive region. Protein S acts as a cofactor to activated protein C. Thus function of protein S is lost upon thrombin cleavage, suggesting that the thrombin-sensitive region interacts with APC on the phospholid surface.
Recent data suggest that factor V and protein S work in synergy as phospholipid-bound cofactors to APC in the degradation of factor VIIIa and that factor VIIIa is preferred over factor Va as APC-substrate. Thus complicated multimolecular complexes, which are the result of protein-protein as well as protein-phospholipid interactions, appear to form the basis for efficient cleavage and inhibition of factors VIIIa and Va.
活化蛋白C(APC)抵抗是目前所描述的静脉血栓形成最常见的危险因素,它是由凝血因子V基因的单点突变引起的。因此,APC对活化凝血因子V的灭活作用受损,这导致血液高凝状态以及终身血栓形成风险增加。蛋白S作为一种抗凝蛋白的重要性体现在蛋白S缺乏与静脉血栓形成之间的关联上。本文的目的是探讨凝血因子V和蛋白S作为活化蛋白C辅助因子作用的最新进展。
本综述所研究的材料包括该领域的几篇个人论文,以及发表在《科学引文索引》收录期刊上的文章和摘要。
凝血因子V和VIII是同源的高分子量糖蛋白,具有相似的功能特性。凝血因子Va和VIIIa与带负电荷的磷脂结合,分别作为凝血因子Xa和IXa的高亲和力受体/辅助因子发挥作用。凝血因子Va和VIIIa分别使凝血酶原和凝血因子Xa的活化速率至少提高10³倍。APC的强效抗凝活性是通过降解凝血因子VIIIa和Va介导的,从而导致对X酶和凝血酶原酶活性的抑制。APC特异性降解膜结合的活化形式的凝血因子V和VIII,而未活化的凝血因子V和VIII是APC的不良底物。成熟的人蛋白S是一种由多个结构域组成的单链糖蛋白,包括一个凝血酶敏感区域。蛋白S作为活化蛋白C的辅助因子发挥作用。因此,蛋白S的功能在凝血酶裂解后丧失,这表明凝血酶敏感区域在磷脂表面与APC相互作用。
最近的数据表明,凝血因子V和蛋白S作为与磷脂结合的辅助因子协同作用于APC,参与凝血因子VIIIa的降解,并且凝血因子VIIIa作为APC底物比凝血因子Va更受青睐。因此,由蛋白质 - 蛋白质以及蛋白质 - 磷脂相互作用产生的复杂多分子复合物似乎构成了有效裂解和抑制凝血因子VIIIa和Va的基础。